hrp0084fc9.4 | Beta cell disorders | ESPE2015

Novel Molecular Mechanisms of Congenital Hyperinsulinism due to Autosomal Dominant Mutations in ABCC8

Nessa Azizun , Aziz Qadeer , Thomas Alison , Harmer Stephen , Flanagan Sarah , Ellard Sian , Kapoor Ritika , Tinker Andrew , Hussain Khalid

Background: Dominant mutations in ABCC8 can cause congenital hyperinsulinism (CHI), which is characterised by unregulated insulin secretion.Objective and hypotheses: To understand the molecular basis of medically unresponsive CHI due to dominant ABCC8 mutations.Method: We investigated ten patients with diazoxide unresponsive CHI who required a near total pancreatectomy. DNA sequencing revealed seven dominant heter...

hrp0094p2-182 | Fat, metabolism and obesity | ESPE2021

Describing the Natural History of Clinical, Biochemical and Radiological outcomes of children with Familial Partial Lipodystrophy type 2 (FPLD2) attending a National Service for Severe Insulin Resistance: a Retrospective Cohort Study

Xuan Zhong Zhu , Stears Anna , Harris Julie , Wilber Ellen , Savage David , O’Rahilly Stephen , Williams Rachel ,

Background: FPLD2 results from autosomal dominant mutations in the LMNA gene. The physical appearance develops through adolescence where subcutaneous fat deposits of the limbs, trunk, buttocks and legs do not develop resulting in a muscular appearance. The metabolic phenotype includes elevations in triglyceride concentrations and hepatosteatosis with resultant insulin resistance. Co-morbidities that may manifest during young adulthood include early-onset diabe...

hrp0095fc11.4 | Late Breaking | ESPE2022

CRN04777, an oral, nonpeptide selective SST5 receptor agonist, dose-dependently suppresses both fasting and stimulated insulin secretion: results from a first in human study

Ferrara-Cook Christine , Luo Rosa , De la Torre Eduardo , Wang Yang , Betz Stephen , Lagast Hjalmar , Struthers Scott , Hovelmann Ultike , Heise Tim , Krasner Alan

Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycemia in neonates, infants, and children, and is caused by genetic mutations in pancreatic beta-cells. Current therapies are burdensome, have limited efficacy, and are associated with significant morbidity. CRN04777 is a potent, orally-bioavailable, selective SST5 agonist that suppresses insulin secretion in the terminal steps of the insulin secretion pathway and could be useful for patients with con...

hrp0089fc9.5 | Pituitary, neuroendocrinology and Puberty 1 | ESPE2018

National Multidisciplinary Decision-Making Guideline for Children and Young People (Idiopathic Thickened Pituitary Stalk and/or Idiopathic Central Diabetes Insipidus

Cerbone Manuela , Bulwer Chloe , Ederies Ashraf , Vallabhaneni Kirtana , Ball Stephen , Kamaly Ian , Grossman Ashley , Gleeson Helena , Korbonits Marta , Nanduri Vasanta , Tziaferi Vaya , Jacques Tom , Visser Johannes , Spoudeas Helen A

Background: Thickening of the Pituitary Stalk (TPS) and/or Central Diabetes Insipidus (CDI) can occour in isolation or synchronously/metachronously in the same patient. Due to their rarity and wide spectrum of underlying aetiologies they represent a diagnostic and management conundrum.Aim: To develop a high-quality national multidisciplinary guideline for the assessment and management of children and young people (CYP) before their 19th birthd...

hrp0086fc5.1 | Management of Disorders of Insulin Secretion | ESPE2016

The Anti-diabetic Drug, Metformin, Suppresses Adipogenesis through both AMP-activated Protein Kinase (AMPK)-dependent and AMPK-independent Mechanisms

Chen Suet Ching , Brooks Rebecca , Houskeeper Jessica , Bremner Shaun K , Dunlop Julia , Viollet Benoit , Salt Ian P , Ahmed S Faisal , Yarwood Stephen J

Background and aim: Metformin is widely used in Type 2 diabetes, with increasing reports of a potential bone protective role. We investigated the role of AMPK in mediating the effects of metformin on mesenchymal stem cell (MSC) differentiation to either osteoblasts or adipocytes.Methods: Confluent mouse MSCs (C3H10T1/2), wild type (WT) and AMPK knockout (KO) mouse embryo fibroblasts (MEFs) were treated with metformin(500 μM), AMPK-activator A769662(...

hrp0082p2-d3-354 | Diabetes (2) | ESPE2014

An Infant with a Novel Kir6.2 Mutation Causing Neonatal Diabetes and Unexplained Lack of Response to Sulphonylurea

O'Connell Susan M , Mc Donald Aoife , O'Toole Norma , Bradfield Anne , Bradley Maura , Hattersley Andrew , Ellard Sian , Proks Peter , Mattis Katia K , Ashcroft Frances , O'Riordan Stephen M P

Background: Neonatal diabetes (NDM) is defined as diabetes developing before 6 months of age, affecting one in 100 000 live births. Permanent NDM is diagnosed in the first 6 months of life with no remission. The majority have a mutation in the ATP-sensitive potassium (KATP) channel (KCNJ11 in 31%, ABCC8 in 13%). Autosomal dominant and recessive forms are described. The majority of patients with NDM caused by KATP mutations respond to sulphonylureas.<p...

hrp0084fc11.2 | Neuroendocrinology | ESPE2015

Functional Characterisation of a POU1F1 Mutation Unexpectedly Associated with Isolated Growth Hormone Deficiency (IGHD): A Novel Aetiology of IGHD

Sobrier Marie-Laure , Tsai Yu-Cheng , Perez Christelle , Leheup Bruno , Bouceba Tahar , Duquesnoy Philippe , Sizova Daria , Liebhaber Stephen , Cooke Nancy E , Amselem Serge

Background: In humans, the GHN gene transcription is under the control of a Locus Control Region (LCR) enhancer, HSI, located 14.5 kb 5′ to the hGHN promoter. POU1F1, a pituitary-specific transcription factor, plays an essential role in the specification of the somatotroph, lactotroph and thyrotroph lineages and the activation of GHN, PRL and TSH gene transcription. All POU1F1 mutations so far reported have been linke...

hrp0097p1-279 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

A Year-Long, National Trial of Prospective CGM Use in Families with Hyperinsulinism

Worth Chris , Worthington Sarah , Auckburally Sameera , Ahmad Sumera , O'Shea Elaine , Ferrera-Cook Chris , F Betz Stephen , Salomon-Estebanez Maria , Banerjee Indraneel

Introduction: Congenital hyperinsulinism (CHI) is the commonest cause of severe hypoglycaemia in early childhood but glycaemic characterisation remains scarce. Continuous glucose monitoring (CGM) offers a deep understanding of glycaemic control to understand disease burden, individualise patient care and inform therapeutic trials in CHI. Preliminary studies suggest inadequate accuracy and no efficacy of standalone CGM to reduce hypoglycaemia. Provision is hist...

hrp0092p1-300 | Adrenals and HPA Axis (2) | ESPE2019

Growth Trajectory and Final Height in Children with Non Classical Congenital Adrenal Hyperplasia

Wasniewska Malgorzata , Morabito Letteria Anna , Baronio Federico , Einaudi Silvia , Salerno Maria Carolina , Bizzarri Carla , Russo Gianni , Chiarito Mariangela , Grandone Anna , Guazzarotti Laura , Spinuzza Antonietta , Di Carlo Silvia , Ortolano Rita , Balsamo Antonio , Abrigo Enrica , Ferroli Barbara Baldini , Alibrandi Angela , Capalbo Donatella , Faienza Maria Felicia

Background: Subjects with non classical congenital adrenal hyperplasia (NCCAH) often present an increased growth velocity secondary to elevation of adrenal androgens that promote early bone maturation and compromise final height (FH). The aim of the study was to analyze prognostic factors affecting growth trajectory and FH in children with NCCAH.Design: retrospective, multicentric studyStud...

hrp0084fc1.3 | Adrenal | ESPE2015

Aldosterone and Mineralocorticoid Receptor as Inducers of Immune Markers in Peripheral Blood Mononuclear Cells: Beyond Elevating Blood Pressure

Vecchiola Andrea , Munoz-Durango Natalia , Cifuentes Mariana , Lagos Carlos , Fuentes Cristobal , Gonzalez Luis-Martin , Ortiz David , Carvajal Cristian , Tapia-Castillo Alejandra , Valdivia Carolina , Martinez-Aguayo Alejandro , Allende Fidel , Solari Sandra , Bancalari Rodrigo , Garcia Hernan , Campino Carmen , Baudrand Rene , Kalergis Alexis , Fardella Carlos E

Background: In vitro studies suggest a broader role for aldosterone, beyond elevating blood pressure. Clinical data support the notion that aldosterone can directly alter the function of the immune system and can participate in low-grade inflammation which leads to blood pressure elevation and end organ damage.Objective and hypothesis: To assess in humans, whether aldosterone plasma levels and mineralocorticoid receptor (MR) expression associate...